An anti-HIV strategy combining chemotherapy and therapeutic vaccination

被引:17
作者
Rosenwirth, B
Bogers, WMJM
Nieuwenhuis, IG
Ten Haaft, P
Niphuis, H
Kuhn, EM
Bischofberger, N
Erfle, V
Sutter, G
Berglund, P
Liljestrom, P
Uberla, K
Heeney, JL
机构
[1] Biomed Primate Res Ctr, Dept Virol, NL-2280 GH Rijswijk, Netherlands
[2] Biomed Primate Res Ctr, Dept Anim Sci, NL-2280 GH Rijswijk, Netherlands
[3] Gilead Sci Inc, Foster City, CA 94404 USA
[4] GSF Forschungszentrum Umwelt & Gesundheit GMBH, Munich, Germany
[5] Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden
[6] Swedish Inst Infect Dis Control, Dept Vaccine Res, Stockholm, Sweden
[7] Univ Leipzig, Inst Virol, Leipzig, Germany
关键词
SHIV; macaques; PMPA; anti-retroviral therapy; vaccines;
D O I
10.1111/j.1600-0684.1999.tb00270.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Combination chemotherapy using potent anti-retroviral agents has led to significant advances in the clinical management of human immunodeficiency virus (HIV) disease. However, the emergence of multiple drug-resistant mutants, the high need for compliance to adhere to demanding drug-dosing schemes, and the remaining toxic side-effects of drugs make the perspective of life-long treatment unattractive and possibly unrealistic. Therefore, means must be sought to shorten the time span during which treatment is necessary. Such means could be to stimulate an efficient immune response during the period of low virus load and restored CD4(+) cell levels, which might be capable of keeping the virus under long-lasting control after treatment is stopped. Here we tested this concept of combined chemotherapy/therapeutic vaccination in a non-human primate model. Rhesus macaques chronically infected with the chimeric simian/human immunodeficiency virus (SHIV) containing the HIV type 1 (HIV-1) HXBc2 gene for reverse transcriptase (RT) in the genomic background of simian immunodeficiency virus (SIV)(mac239) (RT-SHIV) were treated with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA), a potent anti-HIV drug. When virus load had decreased significantly, we immunized with SIV genes env, gag/pol, rev, tat, and nef inserted in two different expression vector systems. Four weeks after the second immunization, drug treatment was stopped. Animals were monitored to determine if virus load stayed low or if it increased again to the original levels and if CD4(+) T-cell levels remained stable. Humoral and cellular immune responses were also measured. This combined chemotherapy/therapeutic vaccination regimen induced a significant reduction in the steady-state level of viremia in one out of two chronically infected rhesus macaques. Chemotherapeutic treatment alone did not achieve reduction of viremia in two chronically infected animals. The nature of the immune responses assumed to have been induced by vaccination in one out of the two monkeys remains to be elucidated.
引用
收藏
页码:195 / 205
页数:11
相关论文
共 27 条
[1]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[2]   DIFFERENTIAL ANTIHERPESVIRUS AND ANTIRETROVIRUS EFFECTS OF THE (S) AND (R) ENANTIOMERS OF ACYCLIC NUCLEOSIDE PHOSPHONATES - POTENT AND SELECTIVE INVITRO AND INVIVO ANTIRETROVIRUS ACTIVITIES OF (R)-9-(2-PHOSPHONOMETHOXYPROPYL)-2,6-DIAMINOPURINE [J].
BALZARINI, J ;
HOLY, A ;
JINDRICH, J ;
NAESENS, L ;
SNOECK, R ;
SCHOLS, D ;
DECLERCQ, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :332-338
[3]  
BALZARINI J, 1996, BIOCHEM BIOPH RES CO, V219, P331
[4]   Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients [J].
BarditchCrovo, P ;
Toole, J ;
Hendrix, CW ;
Cundy, KC ;
Ebeling, D ;
Jaffe, HS ;
Lietman, PS .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (02) :406-413
[5]   Resistance to human immunodeficiency virus type 1 protease inhibitors [J].
Boden, D ;
Markowitz, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2775-2783
[6]   Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients [J].
Calarota, S ;
Bratt, G ;
Nordlund, S ;
Hinkula, J ;
Leandersson, AC ;
Sandström, E ;
Wahren, B .
LANCET, 1998, 351 (9112) :1320-1325
[7]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[8]   Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine [J].
Collier, AC ;
Coombs, RW ;
Schoenfeld, DA ;
Bassett, RL ;
Timpone, J ;
Baruch, A ;
Jones, M ;
Facey, K ;
Whitacre, C ;
McAuliffe, VJ ;
Friedman, HM ;
Merigan, TC ;
Reichman, RC ;
Hooper, C ;
Corey, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1011-1017
[9]   Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults [J].
Deeks, SG ;
Barditch-Crovo, P ;
Lietman, PS ;
Hwang, F ;
Cundy, KC ;
Rooney, JF ;
Hellmann, NS ;
Safrin, S ;
Kahn, JO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2380-2384
[10]   Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy [J].
Gorochov, G ;
Neumann, AU ;
Kereveur, A ;
Parizot, C ;
Li, TS ;
Katlama, C ;
Karmochkine, M ;
Raguin, G ;
Autran, B ;
Debré, P .
NATURE MEDICINE, 1998, 4 (02) :215-221